K Yonemori1, A Hirakawa2, N Komiyama2, T Kouno3, M Ando3, Y Fujiwara3, T Urano2, H Akagawa2, H Maruyama2, S Toyoshima2. 1. Office of New Drug V, Pharmaceuticals and Medical Devices Agency, Tokyo; Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan. Electronic address: kyonemor@ncc.go.jp. 2. Office of New Drug V, Pharmaceuticals and Medical Devices Agency, Tokyo. 3. Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Abstract
BACKGROUND: The objective of this study was to evaluate the age-based enrollment of cancer patients into registration trials of new drug applications or expanding the indications for use. MATERIALS AND METHODS: The data from 234 registration trials in Japan and overseas of 43 drugs, which were reviewed by the Pharmaceuticals and Medical Devices Agency and approved by the Ministry of Health, Labour and Welfare in Japan between 1999 and 2008, were retrospectively analyzed according to the age distribution of enrolled patients. The age distribution of the Japanese cancer population was derived from Cancer Statistics in Japan 2003 and Annual Report on Health, Labour and Welfare 2003-2004. RESULTS: In the Japanese cancer population, the estimated median age of cancer patients is 70 years, and 66% of cancer patients are aged 65 years or more. The estimated median age of cancer patients in all registration trials conducted in Japan was 59 years, whereas it was 55 years in the registration trials conducted overseas. The proportion of patients aged 65 years or more enrolled in registration trials conducted in Japan was 35%; this number was 28% in registration trials conducted overseas. CONCLUSION: Elderly patients are underrepresented in oncology registration trials in Japan.
BACKGROUND: The objective of this study was to evaluate the age-based enrollment of cancerpatients into registration trials of new drug applications or expanding the indications for use. MATERIALS AND METHODS: The data from 234 registration trials in Japan and overseas of 43 drugs, which were reviewed by the Pharmaceuticals and Medical Devices Agency and approved by the Ministry of Health, Labour and Welfare in Japan between 1999 and 2008, were retrospectively analyzed according to the age distribution of enrolled patients. The age distribution of the Japanese cancer population was derived from Cancer Statistics in Japan 2003 and Annual Report on Health, Labour and Welfare 2003-2004. RESULTS: In the Japanese cancer population, the estimated median age of cancerpatients is 70 years, and 66% of cancerpatients are aged 65 years or more. The estimated median age of cancerpatients in all registration trials conducted in Japan was 59 years, whereas it was 55 years in the registration trials conducted overseas. The proportion of patients aged 65 years or more enrolled in registration trials conducted in Japan was 35%; this number was 28% in registration trials conducted overseas. CONCLUSION: Elderly patients are underrepresented in oncology registration trials in Japan.
Authors: T E Hutson; R M Bukowski; B I Rini; M E Gore; J M Larkin; R A Figlin; C H Barrios; B Escudier; X Lin; K Fly; B Martell; E Matczak; R J Motzer Journal: Br J Cancer Date: 2014-01-16 Impact factor: 7.640